US & EU Medical Device Regulatory & Market Access Consulting

Expanding a medical device into the US or European market requires more than regulatory approval. It demands a joined-up strategy that aligns regulatory compliance, market access, reimbursement, and commercial adoption from the outset.

Simplimedica supports:

  • UK & EU companies entering the US market
  • US companies expanding into Europe

We act as a regulatory and commercial bridge between jurisdictions — reducing risk, rework, and time to revenue.

FDA & EU MDR Regulatory Strategy

We deliver jurisdiction-specific regulatory support, not document conversions.

Regulatory services include:

  • FDA 510(k), De Novo, and PMA submission support
  • EU MDR Technical Documentation (Annex II & III)
  • Design Controls aligned to 21 CFR 820 / QMSR
  • Risk management per ISO 14971
  • Clinical and post-market strategy alignment
  • FDA Pre-Sub and Notified Body readiness

Focus: Submissions designed to survive review — not just reach it.

Market Access, Commercialisation & Reimbursement

Approval alone does not guarantee adoption. We help ensure devices are designed, evidenced, and positioned for real-world use.

Market access support includes:

  • US vs EU market entry and sequencing strategy
  • Intended Use and claims aligned to adoption and reimbursement
  • Stakeholder and payer landscape assessment
  • Early reimbursement pathway and risk analysis
  • Commercialisation planning grounded in regulatory reality

Focus: Regulatory success that translates into sustainable revenue.

Commercialisation Planning 

Commercial success depends on designing for adoption, not retrofitting later.

We support:

  • Go-to-market strategy aligned to regulatory constraints
  • Clinical evidence planning to support adoption, not just approval
  • Pricing logic grounded in clinical and economic value
  • Early commercial risk identification (training burden, workflow impact, adoption barriers)
  • Scale-up readiness from pilot to broader deployment

Outcome: Devices designed for real-world use — not just regulatory clearance.

One Strategy — Not Silos

We deliberately integrate:

  • Regulatory claims ↔ clinical evidence ↔ reimbursement logic
  • Design decisions ↔ commercial constraints
  • Approval strategy ↔ post-market adoption

This prevents costly pivots after approval and strengthens investor, payer, and regulator confidence.

Why Simplimedica

✔ Specialist in high-risk, implantable, and innovative devices
✔ PMA-level thinking applied early
✔ Startup-aware, scale-ready delivery
✔ Deep understanding of FDA and EU MDR expectations
✔ Built for companies expanding globally

Who We Support

  • Med-tech startups and scale-ups
  • Class II and Class III devices
  • Implantable, neurotechnology, diagnostics, SaMD
  • Companies planning US FDA approval or EU MDR market entry

Build for Approval — and Adoption

If you are:

  • A UK or EU company planning US FDA submission, or
  • A US company preparing for EU MDR compliance,

Simplimedica helps you move from regulatory approval to market success — with fewer surprises.

Contact us to discuss your US or EU expansion strategy

stars and stripes
Copy link